Pheidias C Wu
Overview
Explore the profile of Pheidias C Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
87
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin C, Chen N, Chen J, Lu C, Hung A, Shiung Y, et al.
Mol Immunol
. 2012 Jun;
52(3-4):190-9.
PMID: 22706073
Type-I hypersensitivity reactions play a critical role in the pathogenesis of various allergic diseases. The successful development of the anti-IgE antibody, omalizumab, has validated IgE as an effective therapeutic target...
2.
Shiung Y, Chiang C, Chen J, Wu P, Hung A, Lu D, et al.
Immunobiology
. 2012 Jan;
217(7):676-83.
PMID: 22226669
A new monoclonal antibody (mAb), specific for human IgE, the central mediator of immediate-type hypersensitivity reactions, has been shown to possess a unique set of binding specificities. The mAb, 8D6,...
3.
Wu P, Chen J, Kawamura S, Roos C, Merker S, Shih C, et al.
Immunogenetics
. 2011 Nov;
64(4):279-87.
PMID: 22068888
Membrane-bound IgE (mIgE) on B lymphocytes is essential for IgE production. Earlier studies showed that the ε chain of mIgE (mε) on human B cells has a "long" isoform, with...
4.
Chen J, Wu P, Hung A, Chu C, Tsai T, Yu H, et al.
J Immunol
. 2010 Jan;
184(4):1748-56.
PMID: 20083663
Membrane-bound IgE (mIgE) is part of the IgE-BCR and is essential for generating isotype-specific IgE responses. On mIgE(+) B cells, the membrane-bound epsilon-chain (mepsilon) exists predominantly in the long isoform,...
5.
Chang T, Wu P, Hsu C, Hung A
Adv Immunol
. 2007 Mar;
93:63-119.
PMID: 17383539
The pharmacological purposes of the anti-IgE therapy are to neutralize IgE and to inhibit its production to attenuate type I hypersensitivity reactions. The therapy is based on humanized IgG1 antibodies...